Pancreatic cancer is one of the most common malignant tumors in man. Despiteadvances in surgical and non-surgical treatments, it remains a big challenge duo to itspoor prognosis; an overall5-year survival rate is only3-5%due to the lack ofsymptoms and screening techniques for early detection, aggressive metastaticbehavior, and resistance to conventional chemotherapy and radiotherapy regimens.Therefore, there is an urgent need to develop novel agents and alternative strategiesfor the treatment of pancreatic ...